• Profile
Close

Low-dose methotrexate for the prevention of atherosclerotic events

New England Journal of Medicine Nov 15, 2018

Ridker PM, et al. - Given that inflammation is causally related to atherothrombosis and a lower rate of cardiovascular events has been reported with canakinumab treatment, researchers investigated if low-dose methotrexate could benefit similarly as an alternative approach to inflammation inhibition. According to results, there was no attenuation in interleukin-1β, interleukin-6, or C-reactive protein concentrations and no fewer cardiovascular events following treatment with low-dose methotrexate in this study population.

Methods

  • This randomized, double-blind trial included 4,786 patients with previous myocardial infarction or multivessel coronary disease and either type 2 diabetes or the metabolic syndrome.
  • Study participants were treated with low-dose methotrexate (at a target dose of 15 to 20 mg weekly) or matching placebo.
  • All participants received 1 mg of folate daily.
  • A composite of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death comprised the primary end point at the onset of the trial.
  • Hospitalization for unstable angina that led to urgent revascularization was added to primary end point near the conclusion of the trial, but before unblinding.

Results

  • A median follow-up of 2.3 years was performed, after which time the trial was stopped.
  • Compared with placebo, no lowering of interleukin-1β, interleukin-6, or C-reactive protein levels was observed with methotrexate.
  • The final primary end point occurred in 201 methotrexate-treated patients and 207 placebo-treated patients.
  • In the methotrexate group and in the placebo group, the original primary end point occurred in 170 and 167 patients, respectively.
  • Compared with placebo, the methotrexate-induced effects included elevations in liver-enzyme levels, reductions in leukocyte counts and hematocrit levels, and a higher incidence of non–basal-cell skin cancers.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay